Narrative review on potential role of gut microbiota in certain substance addiction.

As a neuropsychiatric disorder, substance addiction represents a major public health issue with high prevalence and mortality in many countries. Recently, gut microbiota has been certified to play a part in substance addiction through various mechanisms. Hence, we mainly focused on three substance including alcohol, cocaine and methamphetamine in this review, and summarized their relationships with gut microbiota, respectively. Besides, we also concluded the possible treatments for substance addiction from the perspective of applying gut microbiota. This review aims to build a bridge between substance addiction and gut microbiota according to existing evidences, so as to excavate the possible bi-directional function of microbiota-gut-brain axis in substance addiction for developing therapeutic strategies in the future.

A long-term fatty fish intervention improved executive function in inpatients with antisocial traits and a history of alcohol and drug abuse.

The aim of the present study was to investigate the effects of fatty fish consumption on cognitive functioning in a group of inpatients characterized by antisocial behavior. Eighty-three male forensic inpatients participated in this study. Participants were randomly assigned into a Fish or a Control group (e.g., meat, chicken, pork). One decision-making task, the Iowa Gambling Task (IGT), and one planning task, the Tower of Hanoi (ToH), were administered before (pre-test) and at the end of the intervention period (post-test). For the IGT the Fish group showed improved performance from pre- to post- test. Moreover, the Fish group showed significantly better performance than the Control group on the IGT at post-test. The Fish group also demonstrated improved performance from pre- to post-test on the ToH; however, this was limited to participants with a history of substance abuse. Further, the improvement was only significant for tasks with high working memory load (5-7 move problems), and not for tasks with low working memory load (1-4 move problems). The Control group showed no improvement on any of the tasks regardless of alcohol or drug abuse history. The present study suggests that regular fatty fish consumption may improve executive functions in forensic inpatients with antisocial traits and a history of substance abuse. Thus, the current results may have important implications with regard to health care interventions.

Could the use of energy drinks induce manic or depressive relapse among abstinent substance use disorder patients with comorbid bipolar spectrum disorder?

OBJECTIVE: The potential harmful effects of excessive caffeine consumption remain largely unknown among psychiatric populations. Energy drinks have particularly high levels of caffeine content and have previously been shown to induce psychotic relapse. Clinical observations of three bipolar disorder patients with comorbid substance use disorder revealed an excessive consumption of energy drinks prior to manic or depressive relapse. BACKGROUND: Three patients with bipolar spectrum disorder and comorbid substance use disorder were assessed by a psychiatrist upon re-admission to a rehabilitation centre following manic or depressive relapse. The assessment was based on DSM-IV criteria and performed by a psychiatrist who specialized in bipolar spectrum disorder and comorbidities to determine the presence of manic or depressive relapse. Two patients were diagnosed with bipolar disorder type I, and the third with bipolar disorder type II. All three patients were diagnosed with comorbid substance use disorders and all three abused cocaine. RESULTS: In all three cases, relapse occurred following at least one week of excessive binging on energy drinks, with a maximum daily consumption of nine cans. Following cessation of energy drink consumption, two of the patients remained abstinent from drug use and maintained psychiatric stability. One patient relapsed three months post-treatment and resumed consuming cocaine and energy drinks. CONCLUSIONS: These clinical observations support other case reports that suggest the existence of a potential correlation between excessive energy drink consumption and relapse among psychiatric populations.

Hypogonadism in men receiving methadone and buprenorphine maintenance treatment.

The aim of this study was to determine the prevalence and investigate the aetiology of hypogonadism in men on methadone or buprenorphine maintenance treatment (MMT, BMT). 103 men (mean age 37.6 +/- 7.9) on MMT (n = 84) or BMT (n = 19) were evaluated using hormone assays, body mass index (BMI), serological, biochemical, demographic and substance use measures. Overall 54% of men (methadone 65%; buprenorphine 28%) had total testosterone (TT) <12.0 nm; 34% (methadone 39%; buprenorphine 11%) had TT <8.0 nm. Both methadone- and buprenorphine-treated men had lower free testosterone, luteinising hormone and estradiol than age-matched reference groups. Methadone-treated men had lower TT than buprenorphine-treated men and reference groups. Prolactin did not differ between methadone, buprenorphine groups, and reference groups. Primary testicular failure was an uncommon cause of hypogonadism. Yearly percentage fall in TT by age across the patient group was 2.3%, more than twice that expected normally. There were no associations between TT and opioid dose, cannabis, alcohol and tobacco consumption, or chronic hepatitis C viraemia. On multiple regression higher TT was associated with higher alanine aminotransferase and lower TT with higher BMI. Men on MMT have high prevalence of hypogonadotrophic hypogonadism. The extent of hormonal changes associated with buprenorphine needs to be explored further in larger studies. Men receiving long term opioid replacement treatment, especially methadone treatment, should be screened for hypogonadism. Wide interindividual differences in methadone metabolism and tolerance may in a cross-sectional study obscure a methadone dose relationship to testosterone in individuals. Future studies of hypogonadism in opioid-treated men should examine the potential benefits of dose reduction, choice of opioid medication, weight loss, and androgen replacement.

Comer, demandar e desejar: considerações psicanalíticas sobre o corpo e o objeto na obesidade / Eating, demanding and desiring: psychoanalytical considerations about the body and the object in obesity

O presente estudo discute o tratamento psicanalítico da obesidade, tendo em vista os impasses no manejo dessa problemática. Para tanto, parte-se da análise da patologização do corpo gordo, sua medicalização e os dispositivos biopolíticos de regulação dos corpos que aí figuram para propor uma diferenciação entre o sintoma médico e seu aspecto subjetivo. Contextualizando a cultura na atualidade, que coloca em evidência o corpo, desenvolve-se a disjunção entre necessidade e demanda proposta por Lacan para pensar uma diferença ética que a abordagem psicanalítica da obesidade oferece em relação ao dispositivo médico, na medida em que não se propõe a normalizar os corpos segundo o peso adequado. Essa proposta coloca em pauta a questão do circuito pulsional que, em sua matriz alteritária, estabelece o objeto pulsional vinculado a uma perda originária que, ao mesmo tempo, constitui o desejo como insatisfeito. Considerando que o dispositivo psicanalítico proposto por Freud se estrutura em torno da falta que advém ao final do complexo de Édipo, e que a angústia de castração ocupa lugar prioritário de motor do tratamento, a obesidade se coloca como um problema à medida que a comida comparece revestindo o objeto perdido e fornecendo a consistência à qual o obeso permanece atado. Para pensar de que maneira a psicanálise pode acolher a demanda feita por pacientes obesos e que recursos teórico-clínicos pode-se lançar mão nesses tratamentos, é estabelecido um paralelo com outras problemáticas, tais como: as toxicomanias e a bulimia. Propomos, por fim, que o tratamento psicanalítico visa oferecer um campo de subjetivação que permita a emergência da angústia não somente referida ao corpo e seus excessos, possibilitando a construção de recursos simbólicos necessários à elaboração do real pulsional...

Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers.

OBJECTIVE: Mounting evidence indicates that low levels of n-3 polyunsaturated fatty acids (PUFAs) play a role in the pathophysiology of a large number of psychiatric disorders. In light of the suboptimal n-3 PUFAs intake due to poor dietary habits among substance abusers and the strong associations between aggression, anxiety and substance use disorders we examined if insurance of adequate intakes of n-3 PUFAs with supplementation would decrease their anger and anxiety scores. METHOD: Substance abusers (n=22) were assigned to either 3 g of n-3 PUFAs, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or soybean oil in identically looking capsules. The trial was double-blind, randomized and lasted 3 months. Anger and anxiety scales were administered at baseline and once a month thereafter. Blood samples were collected at baseline and at the end of the trial. RESULTS: Patients' dietary intakes of n-3 PUFAs fell below recommended levels. Assignment to n-3 PUFA treatment was accompanied by significant decreases in anger and anxiety scores compared to placebo assignment. These changes were associated with increases in plasma levels of both EPA and DHA but an increase in EPA was more robustly correlated with low end-of-trial anxiety scores and an increase in DHA was more robustly correlated with low end-of-trial anger scores. CONCLUSION: These pilot data indicate that ensuring adequate n-3 PUFA intake via supplementation benefits substance abusers by reducing their anger and anxiety levels. The strong correlations between an increase in plasma EPA and lower anxiety scores and between an increase in plasma DHA and lower anger scores suggests a need for the further exploration of the differential responses to these two n-3 PUFAs in different psychiatric conditions.

Herbal therapy in the treatment of drug use.

The use of herbs in the treatment of substance abuse is a relatively new phenomenon, although the practice of herbalism goes back to the dawn of humanity. Herbs are natural botanical substances which have noticeable effects on the human organism. Throughout history man has used herbs for nutritional and healing purposes as well as for getting high. Most current treatment programs for substance abusers take into account only a small portion of the healing spectrum (e.g., psychological counseling, methadone, self-help, therapeutic community). There is a growing awareness of and concern to develop programs for substance abusers which utilize a holistic approach to deal with the mental, physical, emotional, and spiritual problems accompanying substance abuse. The purpose of this article is to review the use of herbal therapy in the treatment of drug abusers. An annotated bibliography is provided.